Allegro Ophthalmics

Allegro Ophthalmics is a private, clinical-stage biotech developing a novel class of 'mitochondrial stabilizer' therapies for major ocular diseases. Its lead asset, risuteganib, has shown promise in Phase 2a for intermediate dry AMD and is now in Phase 2b/3 planning under an FDA Special Protocol Assessment (SPA), with a licensee advancing Phase 3 trials in China. The company's platform targets integrin dysregulation to address mitochondrial dysfunction and oxidative stress, aiming to provide treatment options for patients who inadequately respond to current therapies.

Novel integrin-regulating therapy platform focused on mitochondrial stabilization and downregulation of oxidative stress response to restore cellular homeostasis in ocular tissues.

In dry AMD, Allegro competes with numerous biotechs developing complement inhibitors, neuroprotectants, and other modalities, though risuteganib's mitochondrial stabilizer mechanism is distinct. In dry eye disease, the market is saturated with anti-inflammatories and lubricants, so ALG-1007 must demonstrate superior efficacy in addressing underlying pathophysiology to gain share.